Elbasvir–grazoprevir for treating chronic hepatitis C - guidance (TA413)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
26 October 2016

Abstract

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

Is this guidance up to date?

Next review: 2019

Guidance development process

How we develop NICE technology appraisal guidance